Linked Life Data

7905200

Source:http://linkedlifedata.com/resource/pubmed/id/7905200

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1994-3-3
pubmed:abstractText
Receptor scintigraphy with 111In-pentetreotide is a complementary imaging technique with a sensitivity of 88% for the localization of the primary tumor and its metastases in patients presenting with the clinical and biochemical symptoms of an endocrine tumor of the gastrointestinal tract or the pancreas. As a whole-body scintigraphic technique it covers all body regions and is also able to reveal small tumors which can only be detected with difficulty or not at all by the usual imaging methods. In 104 patients with GEP tumors or after operative removal of such tumors, receptor scintigraphy proved to be superior to ultrasound and computed tomography in 34%, equal in 52% and inferior in 14% of the cases.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0029-5566
pubmed:author
pubmed:issnType
Print
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
299-305
pubmed:dateRevised
2007-1-12
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
[Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors].
pubmed:affiliation
Abteilung für Klinische Nuklearmedizin, Philipps-Universität Marburg, FRG.
pubmed:publicationType
Journal Article, English Abstract